Kiniksa reports Q3 EPS 23c, consensus 37c

Reports Q3 revenue $180.9M, consensus $167.36M. “Year to date, ARCALYST revenue has continued to grow, with the expanding adoption of IL-1alpha & IL-1beta inhibition for recurrent pericarditis driving a significant increase in active commercial patients and duration of therapy. As a result, we are raising our 2025 ARCALYST net sales guidance to between $670M and $675M from between $625M and $640M,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa (KNSA). “In our clinical portfolio, we believe the development of KPL-387 positions our IL-1alpha & IL-1beta inhibition franchise for continued success and could offer an important advancement in the treatment options available to patients with recurrent pericarditis, potentially expanding penetration into the addressable market. We are on-track for data from the Phase 2 dose-focusing portion of the KPL-387 Phase 2/3 recurrent pericarditis trial in the second half of 2026.”